Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test
Research Report

Share on Stocktwits


An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application.

In a Nov. 30 research note, analyst Ram Selvaraju reported CytoDyn Inc. (CYDY:OTCQB) announced positive clinical data for its PCaTest, a gene-based prostate cancer prognostic test. PCaTest applies proprietary algorithms to 14 gene biomarker signatures to determine "therapeutic substratification" and prognosis of a patient's prostate cancer.

Selvaraju noted that "together with data from three prior studies of 348 patient samples, the new results support the company's strategy for seeking U.S. Food and Drug Administration (FDA) approval for the PCaTest."

The findings showed "substantial additive discriminative value for predicting outcomes of prostate cancer patients compared to the Gleason score, the current standard," in that it characterized patients as being at low or high risk, Selvaraju added.

Specifically, the recent clinical study assessed 218 patients who had been followed for 10 or more years after their initial prostate cancer diagnosis. These patients had a Gleason score of 7, "considered indeterminate or intermediate."

Selvaraju also reported the FDA approved CytoDyn's investigational new drug application for a Phase 1b/2 trial of PRO 140, or leronlimab, in patients with metastatic triple negative breast cancer (TNBC). The study, to be conducted from five already chosen clinical sites, will enroll up to 48 patients. CytoDyn plans an initial data readout on the first dosed patients in Q1/19.

"Leronlimab may provide a viable treatment option to TNBC patients with poor prognosis, in our view," wrote Selvaraju.

Also slated for Q1/19 is completion of biologics license application filings, to get underway soon, for approval of its PRO 140 as a combination therapy for human immunodeficiency virus (HIV). "PRO 140's efficacy compares favorably to those of marketed drugs for the CCR5-tropic HIV-1 population, in our view, and suggests attractive commercial prospects," Selvaraju indicated.

H.C. Wainwright reiterated its Buy rating and $1.50 per share price target on CytoDyn, whose stock is currently trading at around $0.57 per share.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., CytoDyn Inc., Company Update, November 30, 2018

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Raghuram Selvaraju, Ph.D., Yi Chen, Ph.D. CFA and Karthik Sunkesula, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of CytoDyn, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of October 31, 2018 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of CytoDyn, Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from CytoDyn, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in CytoDyn, Inc. as of the date of this research report.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe